Invention Grant
- Patent Title: Site-specific glycoengineering of targeting moieties
-
Application No.: US17215674Application Date: 2021-03-29
-
Publication No.: US11697690B2Publication Date: 2023-07-11
- Inventor: Luis Avila , Clark Pan , Huawei Qiu , Qun Zhou
- Applicant: Genzyme Corporation
- Applicant Address: US MA Cambridge
- Assignee: GENZYME CORPORATION
- Current Assignee: GENZYME CORPORATION
- Current Assignee Address: US MA Cambridge
- Agency: Lathrop GPM LLP
- Agent James H. Velema; Judith L. Stone-Hulslander
- The original application number of the division: US14662187 2015.03.18
- Main IPC: C07K16/32
- IPC: C07K16/32 ; C07K16/28 ; C07K16/40 ; A61K47/68 ; A61K47/61 ; A61K47/60

Abstract:
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
Public/Granted literature
- US20220119547A1 SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES Public/Granted day:2022-04-21
Information query